X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
1. Cortisol 17-butyrate
2. Hydrocortisone 17-butyrate
3. Hydrocortisone-17-butyrate
4. Locoid
1. Hydrocortisone 17-butyrate
2. Cortisol 17-butyrate
3. Hydrocortisone-17-butyrate
4. 13609-67-1
5. Locoid
6. Hydrocortisone-17alpha-butyrate
7. 17-o-butyrylcortisol
8. 11beta,17,21-trihydroxypregn-4-ene-3,20-dione 17-butyrate
9. H-17-b
10. Chebi:31674
11. 05rmf7ypwn
12. Mls000028716
13. Mls001076086
14. Laticort
15. Nsc-758433
16. Alfason
17. Hycortate
18. Lacoidon
19. Smr000058859
20. Bucort
21. Lacoid
22. Dsstox_cid_25896
23. Dsstox_rid_81208
24. Dsstox_gsid_45896
25. 11beta,21-dihydroxy-3,20-dioxopregn-4-en-17-yl Butanoate
26. 11beta,21-dihydroxy-17alpha-butyryloxy-4-pregnene-3,20-dione
27. Hb(sub 17)
28. Cas-13609-67-1
29. Cortisol, 17-butyrate
30. H.17b
31. [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] Butanoate
32. Einecs 237-093-4
33. Unii-05rmf7ypwn
34. Ncgc00095037-01
35. Locoid (tn)
36. Hydrocortisone-butyrate
37. Opera_id_188
38. Hydrocortisone Butyrate [usan:usp:ban:jan]
39. Butyric Acid Hydrocortisone
40. Epitope Id:119710
41. 11-beta,17-alpha,21-trihydroxy-4-pregnene-3,20-dione 17-alpha-butyrate
42. Pregn-4-ene-3,20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (11-beta)-
43. Schembl4695
44. Chembl1683
45. Mls002207122
46. Dtxsid4045896
47. Bdbm323672
48. Hms2231b16
49. Bcp11925
50. Hy-b0983
51. Zinc3977794
52. Tox21_111397
53. Ac-492
54. Hydrocortisone Butyrate (jp17/usp)
55. Hydrocortisone Butyrate [jan]
56. S6590
57. Hydrocortisone Butyrate [usan]
58. Akos015895443
59. Pregn-4-ene-3,20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (11.beta.)-
60. Pregn-4-ene-3,20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (11beta)-
61. Tox21_111397_1
62. Cs-4474
63. Db14540
64. Hydrocortisone Butyrate [mart.]
65. Hydrocortisone Butyrate [vandf]
66. Nsc 758433
67. Hydrocortisone Butyrate [usp-rs]
68. Hydrocortisone Butyrate [who-dd]
69. Hydrocortisone 17-butyrate [mi]
70. Ncgc00274077-01
71. Us10188667, Example 00013
72. Us10188667, Example 00024
73. (1s,10s,11s,15s,17s,2r,14r)-17-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyl-5-ox Otetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-6-en-14-yl Butanoate
74. H1506
75. Hydrocortisone Butyrate [orange Book]
76. D01619
77. Hydrocortisone Butyrate [usp Monograph]
78. 609h671
79. A807026
80. Q5954743
81. W-108252
82. Hydrocortisone 17-butyrate 100 Microg/ml In Methanol
83. Hydrocortisone Butyrate (hydrocortisone 17-butyrate)
84. 11.beta.,17,21-trihydroxypregn-4-ene-3,20-dione 17-butyrate
85. Hydrocortisone Butyrate, United States Pharmacopeia (usp) Reference Standard
86. (8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl Butanoate
87. [(8s,9s,10r,11s,13s,14s,17r)-10,13-dimethyl-11-oxidanyl-17-(2-oxidanylethanoyl)-3-oxidanylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] Butanoate
88. Butanoic Acid [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-17-(2-hydroxy-1-oxoethyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] Ester
| Molecular Weight | 432.5 g/mol |
|---|---|
| Molecular Formula | C25H36O6 |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 432.25118886 g/mol |
| Monoisotopic Mass | 432.25118886 g/mol |
| Topological Polar Surface Area | 101 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 817 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 3 | |
|---|---|
| Drug Name | LOCOID |
| Active Ingredient | HYDROCORTISONE BUTYRATE |
| Company | PRECISION DERMAT (Application Number: N018514); PRECISION DERMAT (Application Number: N018652); PRECISION DERMAT (Application Number: N019116); PRECISION DERMAT (Application Number: N022076. Patents: 7378405, 7981877) |
| 2 of 3 | |
|---|---|
| Drug Name | HYDROCORTISONE BUTYRATE |
| Active Ingredient | HYDROCORTISONE BUTYRATE |
| Company | ACTAVIS MID ATLANTIC (Application Number: A205134); GLENMARK GENERICS (Application Number: A202145); TARO PHARM INDS (Application Number: A076364); TARO PHARM INDS (Application Number: A076654); TARO (Application Number: A076842); TELIGENT PHARMA INC (Application Number: A209556) |
| 3 of 3 | |
|---|---|
| Drug Name | LOCOID LIPOCREAM |
| Active Ingredient | HYDROCORTISONE BUTYRATE |
| Company | PRECISION DERMAT (Application Number: N020769) |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AB - Corticosteroids, moderately potent (group ii)
D07AB02 - Hydrocortisone butyrate
Absorption
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
Route of Elimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Primarily hepatic via CYP3A4
6-8 hours
Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Market Place
